摘要
目的了解广州地区喹诺酮类耐药铜绿假单胞菌的耐药性及泵抑制剂对其耐药水平降低的作用，并调查血清型分布情况。方法用法国生物梅里埃公司的微生物鉴定和药敏分析系统VITEK-2对127株铜绿假单胞菌进行鉴定和药敏检测，并采用羰酰氰基-对-氯苯胺（CCCP）与环丙沙星共同作用，以琼脂稀释法测定耐药菌的最低抑菌浓度（MIC）的变化，同时用玻片凝集法对耐药株进行血清学分型。结果环丙沙星耐药菌对哌拉西林／他唑巴坦（65．5％）的敏感率最高，只有阿米卡星（64．4％）、哌拉西林（51．7％）和妥布霉素（50．6％）的敏感率大于50．0％，而敏感菌对美罗培南（97．5％）及左氧氟沙星（97．5％）的敏感率最高，妥布霉素（95．0％）次之，对临床常用的13种抗生素，耐药菌较敏感菌的敏感性明显降低（P值均〈0．001）；耐药菌受泵抑制CCCP作用，MIC降低1～4个稀释度；血清分型率为93．1％，耐药菌的血清型以B型（20．7％）和L型（19．5％）为主。结论耐喹诺酮类铜绿假单胞菌对临床常用抗生素的敏感性降低，并呈多重耐药，使用抗生素＋泵抑制剂可提高药物对铜绿假单胞菌的敏感性；血清学分型可以快速简单地监测铜绿假单胞菌在医院内的流行情况。
Objectives To explore the antibiotic resistance and reducing effect on quinolone resistance of Pseudomonas aeruginosa using pump inhibitor, and to study the serotyping in Guangzhou. Methods 127 strains P. aeruginosa were identified and the antibiotic sensitivity test were performed by VITEK-2 system. Using the method of agar dilution to measure the Minimum inhibitory concentrations （ MIC ） of the quinolone-resistant isolates, along with carbonyl cyanide-3- chloro-phenylhydrazone （CCCP） and ciprofloxacin. And those isolates were typed with IATS glass agglutination. Results The sensitivity rate of quinolone-resistant strains were piperacillin/tazobactam （65.5%）, amikacin（ 64.4% ）, piperacillin （51.7% ）, tobramycinfour（ 50. 6% ）. And the sensitivity rate of quinolone-sensitive strains were meropenem （97.5%）, levofloxacin（97.5% ） ,tobramycinfour（95.0% ）. To 13 kinds of antibiotics, the rates of resistance isolates were apparently lower than the sensitive isolates （P 〈 0.001 ）. The pump inhibitor CCCP could reduce MIC. Typing rate was 93.1%, serotype of resistance isolates were type B （20.7%）, type L （ 19.5% ）. Conclusions To all antibiotics the sensitivity rate of qulnolone-resistant P. aerug/nosa were decreased, and had multidrug resistance to antibiotics tested. By using antibiotic with pump inhibitor, the sensitivity rate can be increased. Serotyping can be used to analyse the hospital epidemic of P. aeruginosa.
出处
《中国微生态学杂志》
CAS
CSCD
2007年第2期167-169,共3页
Chinese Journal of Microecology
基金
广州市教育局立项资助项目(项目编号1044)
广东省医学科研基金立项项目(项目编号A2003296)
